Sign in
Not yet taking people in FrancePhase 1/2

SAR447998 in adults with lupus or rheumatoid arthritis that has not responded to treatment

Tests SAR447998 in adults with lupus or rheumatoid arthritis not helped by other treatments.

Key facts

Who runs it
Sanofi-Aventis Recherche & Developpement
Where
Marseille, Montpellier Cedex 5, and Pessac, FranceSee the 3 sites
Trial code
Registry title
Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
10 people, planned
Started
19 Oct 2026
Expected to end
1 Oct 2030
Type of study
Interventional
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with refractory systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It tests the safety and early effect of SAR447998.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Refractory systemic lupus erythematosus or rheumatoid arthritis.

Where in France

  • Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
  • Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
SAR447998 in adults with lupus or rheumatoid arthritis that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 October 2026